Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19865806 | 0.84 | VNN1 (0.30) | — | |
| SCHEMBL22023887 | 0.79 | CTDSP1 (0.35) | — | |
| SCHEMBL24065677 | 0.78 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL21965416 | 0.78 | CYP19A1 (0.33) | — | |
| SCHEMBL21169013 | 0.77 | KIF11 (0.34) | KIF11 | |
| SCHEMBL19670976 | 0.76 | TAAR1 (0.50) | KIF11 | |
| SCHEMBL21191684 | 0.75 | CNR2 (0.41) | — | |
| SCHEMBL17307729 | 0.74 | GOT1 (0.33) | — | |
| SCHEMBL24065679 | 0.74 | CYP19A1 (0.47) | KIF11 | |
| SCHEMBL21039533 | 0.73 | CNR2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236111-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200377519-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-12-03 | — | — | US | disclosed |
| US-10428070-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190177320-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236111-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | KIF11 3074/4885 |
| US-20190177320-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | KIF11 3074/4885 |
| US-10428070-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | KIF11 3074/4885 |
| US-20200377519-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | KIF11 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.